Biofrontera (BFRI) Expected to Post Earnings on Wednesday

Biofrontera (NASDAQ:BFRI) is expected to be announcing its Q2 2026 results after the market closes on Wednesday, August 12th. Analysts expect Biofrontera to post earnings of ($0.1050) per share and revenue of $9.50 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 12:30 PM ET.

Biofrontera (NASDAQ:BFRI) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.29). The business had revenue of $10.08 million during the quarter, compared to analyst estimates of $10.25 million. Biofrontera had a negative net margin of 25.66% and a negative return on equity of 515.34%. On average, analysts expect Biofrontera to post $-0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Biofrontera Stock Up 2.5%

Shares of NASDAQ:BFRI opened at $1.22 on Wednesday. The business has a 50-day moving average price of $1.03 and a 200 day moving average price of $0.96. The company has a current ratio of 1.20, a quick ratio of 1.09 and a debt-to-equity ratio of 0.78. The company has a market capitalization of $15.62 million, a price-to-earnings ratio of -1.26 and a beta of 0.78. Biofrontera has a 12-month low of $0.55 and a 12-month high of $1.27.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Wall Street Zen raised shares of Biofrontera to a “hold” rating in a research report on Saturday, July 18th. Weiss Ratings upgraded shares of Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. Finally, Zacks Research raised shares of Biofrontera from a “strong sell” rating to a “hold” rating in a research note on Monday. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold”.

Hedge Funds Weigh In On Biofrontera

An institutional investor recently raised its stake in Biofrontera stock. Geode Capital Management LLC lifted its holdings in shares of Biofrontera Inc. (NASDAQ:BFRI) by 54.2% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 65,677 shares of the company’s stock after purchasing an additional 23,074 shares during the quarter. Geode Capital Management LLC owned about 0.56% of Biofrontera worth $37,000 as of its most recent filing with the SEC. 10.08% of the stock is owned by institutional investors and hedge funds.

Biofrontera Company Profile

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.